Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia

Cancer Genet Cytogenet. 2009 Apr 1;190(1):46-8. doi: 10.1016/j.cancergencyto.2008.11.012.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Amino Acid Substitution / genetics
  • Antineoplastic Agents / therapeutic use
  • Base Sequence
  • Benzamides
  • Chromosomes, Human, Pair 19*
  • Chromosomes, Human, Pair 3*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Glutamic Acid / genetics
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Middle Aged
  • Mutation, Missense
  • Piperazines / therapeutic use
  • Prognosis
  • Pyrimidines / therapeutic use
  • Translocation, Genetic*
  • Trisomy*
  • Valine / genetics

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Glutamic Acid
  • Imatinib Mesylate
  • Valine